The first identification of three AdIRAK2 genes from an evolutionarily important amphibian Andrias davidianus and their involvement in NF-κB activation and inflammatory responses

Chen, David D. Y.; Li, Bang-Ze; Xu, Wenbin; Zhang, Yanmei; Li, Bing-Wu; Cheng, Yuan-Xin; Xiao, Yi; Lin, Chen-Yang; Dong, Wei-Ren; Shu, Miao-An

doi:10.1016/j.dci.2022.104585

Cited by 2 publications

(1 citation statement)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TNF-α activates sphingomyelinases, which, in turn, promote the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) [ 63 ]. NF-κB, as a transcription factor, promotes the activation of several inflammatory cytokine genes, including interleukin-1β (IL-1β), interleukin-6 (IL-6), interleukin-8 (IL-8) and pro-inflammatory enzymes, including monocyte chemoattractant protein-1 (MCP-1) and cyclo-oxygenase 2 (COX-2) [ 64 , 65 ], the latter then promoting the upregulation of prostaglandin E2 (PGE2).…”

Section: Ceramidesmentioning

confidence: 99%

Ceramides in Autoimmune Rheumatic Diseases: Existing Evidence and Therapeutic Considerations for Diet as an Anticeramide Treatment

et al. 2023

View full text Add to dashboard Cite

Autoimmune rheumatic diseases (AIRDs) constitute a set of connective tissue disorders and dysfunctions with akin clinical manifestations and autoantibody responses. AIRD treatment is based on a comprehensive approach, with the primary aim being achieving and attaining disease remission, through the control of inflammation. AIRD therapies have a low target specificity, and this usually propels metabolic disturbances, dyslipidemias and increased cardiovascular risk. Ceramides are implicated in inflammation through several different pathways, many of which sometimes intersect. They serve as signaling molecules for apoptosis, altering immune response and driving endothelial dysfunction and as regulators in the production of other molecules, including sphingosine 1-phosphate (S1P) and ceramide 1-phosphate (C1P). With lipid metabolism being severely altered in AIRD pathology, several studies show that the concentration and variety of ceramides in human tissues is altered in patients with rheumatic diseases compared to controls. As a result, many in vitro and some in vivo (animal) studies research the potential use of ceramides as therapeutic targets in rheumatoid arthritis (RA), ankylosing spondylitis, systemic lupus erythematosus, fibromyalgia syndrome, primary Sjögren’s syndrome, systemic sclerosis, myositis, systemic vasculitis and psoriatic arthritis. Furthermore, the majority of ceramide synthesis is diet-centric and, as a result, dietary interventions may alter ceramide concentrations in the blood and affect health. Subsequently, more recently several clinical trials evaluated the possibility of distinct dietary patterns and nutrients to act as anti-ceramide regimes in humans. With nutrition being an important component of AIRD-related complications, the present review details the evidence regarding ceramide levels in patients with AIRDs, the results of anti-ceramide treatments and discusses the possibility of using medical nutritional therapy as a complementary anti-ceramide treatment in rheumatic disease.

show abstract

Section: Ceramidesmentioning

confidence: 99%